ArticleFrontiers in oncology2025
Feasibility study for proton dose calculation of esophageal squamous cell carcinoma based on stopping power ratio directly derived from dual energy CT.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Research progress of the clinical application of dual-layer spectral computed tomography in gastrointestinal malignancies.World journal of radiology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the feasibility of proton therapy planning using stopping power ratio (SPR) maps directly generated from spectral CT raw data, and to perform a comparative evaluation of dose calculation uncertainties between SPR maps derived from conventional CT Hounsfield Unit (HU) conversion and direct spectral CT SPR generation. Materials and methods: A retrospective analysis was conducted on 30 patients with mid-thoracic esophageal squamous cell carcinoma (ESCC) who underwent pre-treatment spectral CT imaging. Target volumes and organs at risk (OARs) were delineated on contrast-enhanced CT images and subsequently registered to both non-contrast CT and SPR maps. Three treatment plans were generated: Intensity-modulated radiotherapy (IMRT) plan based on conventional CT, Intensity-modulated proton therapy (IMPT) plan using HU-SPR conversion, IMPT plan utilizing direct SPR maps (IMPT-SPR) from spectral CT. Dose-volume parameters for target volumes and OARs (lungs, heart, spinal cord) were systematically analyzed. Comparative dosimetric analyses were performed among the three plans and between paired groups. Results: All plans met clinical radiotherapy requirements. For OARs (lungs, heart), IMPT plans demonstrated significantly lower dose-volume parameters compared to IMRT, except for maximum dose (Dmax). Between the two IMPT approaches, no statistically significant differences were observed in dose-volume parameters ( Conclusion: IMPT demonstrated superior OAR sparing compared to IMRT. For mid thoracic ESCC patients under proton therapy, dose calculations based on CT-HU conversion was showed comparable dosimetric impact to DECT-derived SPR in terms of target coverage and OAR protection. These findings support the clinical feasibility of conventional CT-based proton therapy planning and dose calculation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.